Please login to the form below
salmeterol
This page shows the latest salmeterol news and features for those working in and with pharma, biotech and healthcare.
Is GSK planning to exit the respiratory business?
Much of its recent success was built on the back of combination therapies that were first introduced in the late 1980s, and culminated in its blockbuster Advair/Seretide (salmeterol/fluticasone propionate)
Latest news
-
AZ rival to GSK’s COPD drug Anoro fails head-to-head test
Anoro is one of the drugs GSK is hoping will help replace its COPD blockbuster Seretide/Advair (salmeterol/fluticasone propionate), which has lost patent protection and seen revenues slide in recent
-
GSK gets maintenance indication for Trelegy
of patent protection for COPD blockbuster Seretide/Advair (fluticasone propionate/salmeterol), even though competition in the US has been delayed by stringent FDA requirements for low-cost generics that have delayed
-
FDA hands GSK a reprieve by blocking Novartis generic
All three generics have been flummoxed by the complexity of Advair (salmeterol and fluticasone propionate) and the difficulty of showing sufficient equivalence with the Diskus dry powder inhaler used in the ... Teva won approval for its AirDuo product
-
Gilead’s triple HIV drug approval prompts GSK lawsuit
vaccine Shingrix and recently-approved triple therapy for chronic obstructive pulmonary disorder (COPD) Trelegy - as it faces the imminent threat of generic competition to its big-selling respiratory drug Advair (salmeterol
-
AZ’s COPD triple data sets up market clash with GSK
salmeterol and fluticasone propionate) that was a $7bn product at its peak but has seen sales slip of late, coming in at $3.3bn in the first nine months of 2017.
More from news
Approximately 1 fully matching, plus 84 partially matching documents found.
Latest from PMHub
-
Raising Awareness: It’s World COPD Day today!
Common combinations include fluticasone proprionate/salmeterol and budesonide/formoterol, which are taken twice-daily, and fluticasone furoate/vilanterol, which is taken once-daily (5).
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Global Business Development Director – Health Education
-
excellent commission
-
Account Director, Medical Education
-
Salary TBC
-
Account Director
-
Competitive Salary Offered
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Associate Director
-
£75, 000-90, 000
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Senior Medical Writer
-
Salary TBC
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Senior Account Manager
-
Competitive Salary Offered
-
Account Manager / Account Director
-
Competative
-
Business Director
-
Competitive Salary Offered
-
Medical Writer
-
Salary TBC
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
Subscribe to our email news alerts
- Pfizer takeover rumour ignites Amarin shares
- Welcome to the Communique Awards - Communiqué Awards 2018
- NICE rejects Novartis migraine treatment Aimovig
- GSK upbeat on its return to oncology market
- AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief
- AZ’s Sean Bohen to exit after business overhaul; report
PMHub
Six Degrees Medical Consulting
Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...
Latest intelligence
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
- Digital applications are transforming the market access landscape
- Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
- Escaping the spin cycle of sub-optimal launch
- ...
Quick links
Infographics
